{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:27:47Z","timestamp":1791419267573,"version":"4.3.3"},"reference-count":234,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"publisher","award":["NU23J-02-00015"],"award-info":[{"award-number":["NU23J-02-00015"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009553","name":"Agentura Pro Zdravotnick\u00fd V\u00fdzkum \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bcp.2025.117363","type":"journal-article","created":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T14:13:58Z","timestamp":1758464038000},"page":"117363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"P3","title":["Exploring the potential of soluble guanylyl cyclase stimulators and activators in heart failure"],"prefix":"10.1016","volume":"242","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4397-3991","authenticated-orcid":false,"given":"Olga","family":"Gawrys","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Kala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"\u0160norek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vojt\u011bch","family":"Melenovsk\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Corda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sandner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.bcp.2025.117363_b0005","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.bcp.2025.117363_b0010","unstructured":"T.A. McDonagh, M. Metra, M. Adamo, R.S. Gardner, A. Baumbach, M. Bohm, H. Burri, J. Butler, J. Celutkiene, O. Chioncel, J.G.F. Cleland, A.J.S. Coats, M.G. Crespo-Leiro, D. Farmakis, M. Gilard, S. Heymans, A.W. Hoes, T. Jaarsma, E.A. Jankowska, M. Lainscak, C.S.P. Lam, A.R. Lyon, J.J.V. McMurray, A. Mebazaa, R. Mindham, C. Muneretto, M. Francesco Piepoli, S. Price, G.M.C. Rosano, F. Ruschitzka, A. Kathrine Skibelund, E.S.C.S.D. Group, 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, Eur Heart J 42(36) (2021) 3599-3726."},{"issue":"18","key":"10.1016\/j.bcp.2025.117363_b0015","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.bcp.2025.117363_b0020","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1124\/pharmrev.124.001060","article-title":"Nitric Oxide Signaling and Regulation in the Cardiovascular System: recent advances","volume":"76","author":"Carlstrom","year":"2024","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bcp.2025.117363_b0025","doi-asserted-by":"crossref","unstructured":"P. Sandner, D.P. Zimmer, G.T. Milne, M. Follmann, A. Hobbs, J.-P. Stasch, Soluble Guanylate Cyclase Stimulators and Activators, in: H.H.H.W. Schmidt, Ghezzi, P., Cuadrado, A. (eds) (Ed.), Reactive Oxygen Species. Handbook of Experimental Pharmacology, Springer, Cham, 2021, pp. 355-394.","DOI":"10.1007\/164_2018_197"},{"key":"10.1016\/j.bcp.2025.117363_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.apha.2016.05.001","article-title":"The Endothelium-Dependent Nitric oxide-cGMP Pathway","volume":"77","author":"Monica","year":"2016","journal-title":"Adv. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2025.117363_b0035","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nrcardio.2017.224","article-title":"Nitric oxide signalling in cardiovascular health and disease","volume":"15","author":"Farah","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117363_b0040","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00210-019-01779-z","article-title":"cGMP: a unique 2nd messenger molecule - recent developments in cGMP research and development","volume":"393","author":"Friebe","year":"2020","journal-title":"N-S Arch Pharmacol"},{"key":"10.1016\/j.bcp.2025.117363_b0045","doi-asserted-by":"crossref","unstructured":"F. Hofmann, D. Bernhard, R. Lukowski, P. Weinmeister, cGMP regulated protein kinases (cGK), Handb Exp Pharmacol (191) (2009) 137-62.","DOI":"10.1007\/978-3-540-68964-5_8"},{"issue":"2","key":"10.1016\/j.bcp.2025.117363_b0050","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3390\/ph6020269","article-title":"cGMP-dependent Protein Kinase Inhibitors in Health and Disease","volume":"6","author":"Wolfertstetter","year":"2013","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"10.1016\/j.bcp.2025.117363_b0055","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1515\/hsz-2019-0386","article-title":"The cGMP system: components and function","volume":"401","author":"Hofmann","year":"2020","journal-title":"Biol. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2025.117363_b0060","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/10742484211042706","article-title":"The Role of sGC Stimulators and Activators in Heart failure with Reduced Ejection Fraction","volume":"26","author":"Cordwin","year":"2021","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2025.117363_b0065","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1161\/01.RES.78.1.91","article-title":"Low increase in cGMP induced by organic nitrates and nitrovasodilators improves contractile response of rat ventricular myocytes","volume":"78","author":"Kojda","year":"1996","journal-title":"Circ. Res."},{"issue":"6","key":"10.1016\/j.bcp.2025.117363_b0070","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1161\/01.CIR.93.6.1223","article-title":"Myocardial contractile response to nitric oxide and cGMP","volume":"93","author":"Mohan","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2025.117363_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2015.09.022","article-title":"The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats","volume":"767","author":"Reinke","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117363_b0080","doi-asserted-by":"crossref","unstructured":"M. Gheorghiade, C.N. Marti, H.N. Sabbah, L. Roessig, S.J. Greene, M. Bohm, J.C. Burnett, U. Campia, J.G. Cleland, S.P. Collins, G.C. Fonarow, P.D. Levy, M. Metra, B. Pitt, P. Ponikowski, N. Sato, A.A. Voors, J.P. Stasch, J. Butler, F. Academic Research Team in Heart, Soluble guanylate cyclase: a potential therapeutic target for heart failure, Heart Fail Rev 18(2) (2013) 123-34.","DOI":"10.1007\/s10741-012-9323-1"},{"issue":"1","key":"10.1016\/j.bcp.2025.117363_b0085","doi-asserted-by":"crossref","first-page":"H8","DOI":"10.1152\/ajpheart.01147.2003","article-title":"Nitric oxide's role in the heart: control of beating or breathing?","volume":"287","author":"Paulus","year":"2004","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117363_b0090","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1440-1681.2000.03240.x","article-title":"A short history of nitroglycerine and nitric oxide in pharmacology and physiology","volume":"27","author":"Marsh","year":"2000","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117363_b0095","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/hh0102.102330","article-title":"Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview","volume":"90","author":"Ignarro","year":"2002","journal-title":"Circ. Res."},{"issue":"2 Suppl 3","key":"10.1016\/j.bcp.2025.117363_b0100","first-page":"E239","article-title":"Dietary supplements for improving nitric-oxide synthesis","volume":"63","author":"Kiani","year":"2022","journal-title":"J. Prev. Med. Hyg."},{"issue":"3","key":"10.1016\/j.bcp.2025.117363_b0105","doi-asserted-by":"crossref","DOI":"10.1111\/aas.14575","article-title":"Impact of nitroglycerin-induced vasodilation on stroke volume and diuretic response in acute heart failure: a protocol for a mechanistic trial","volume":"69","author":"Lau","year":"2025","journal-title":"Acta Anaesthesiol. Scand."},{"issue":"3","key":"10.1016\/j.bcp.2025.117363_b0110","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1001\/jamacardio.2024.4417","article-title":"Potassium Nitrate in Heart failure with Preserved Ejection Fraction: a Randomized Clinical Trial","volume":"10","author":"Zamani","year":"2025","journal-title":"JAMA Cardiol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117363_b0115","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nrd2466","article-title":"The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics","volume":"7","author":"Lundberg","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.bcp.2025.117363_b0120","doi-asserted-by":"crossref","DOI":"10.3390\/biom8040134","article-title":"Dietary Nitrate from Beetroot juice for Hypertension: a Systematic Review","volume":"8","author":"Bonilla Ocampo","year":"2018","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.bcp.2025.117363_b0125","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/bcp.12913","article-title":"It is rocket science - why dietary nitrate is hard to 'beet'! Part I: twists and turns in the realization of the nitrate\u2013nitrite\u2013NO pathway","volume":"83","author":"Khatri","year":"2017","journal-title":"Brit J Clin Pharmaco"},{"issue":"18","key":"10.1016\/j.bcp.2025.117363_b0130","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/eurheartj\/ehae100","article-title":"Inorganic nitrate benefits contrast-induced nephropathy after coronary angiography for acute coronary syndromes: the NITRATE-CIN trial","volume":"45","author":"Jones","year":"2024","journal-title":"Eur. Heart J."},{"issue":"18","key":"10.1016\/j.bcp.2025.117363_b0135","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1093\/cvr\/cvac125","article-title":"Natriuretic peptide pathways in heart failure: further therapeutic possibilities","volume":"118","author":"Sangaralingham","year":"2023","journal-title":"Cardiovasc. Res."},{"issue":"2","key":"10.1016\/j.bcp.2025.117363_b0140","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1152\/physrev.00022.2015","article-title":"Molecular Physiology of Membrane Guanylyl Cyclase Receptors","volume":"96","author":"Kuhn","year":"2016","journal-title":"Physiol. Rev."},{"issue":"7","key":"10.1016\/j.bcp.2025.117363_b0145","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/eurheartj\/eht466","article-title":"Natriuretic peptides in cardiovascular diseases: current use and perspectives","volume":"35","author":"Volpe","year":"2014","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.bcp.2025.117363_b0150","first-page":"88","article-title":"Neprilysin Inhibitors in Heart failure: the Science","volume":"8","author":"Bozkurt","year":"2023","journal-title":"Mechanism of Action, Clinical Studies, and Unanswered Questions, JACC Basic Transl Sci"},{"key":"10.1016\/j.bcp.2025.117363_b0155","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ijcard.2018.06.002","article-title":"Natriuretic peptide based therapeutics for heart failure: Cenderitide: a novel first-in-class designer natriuretic peptide","volume":"281","author":"Ichiki","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.bcp.2025.117363_b0160","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1057083","article-title":"Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules","volume":"13","author":"Bondarev","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117363_b0165","doi-asserted-by":"crossref","unstructured":"M.T.M. Nemr, M.A. Abdelaziz, M. Teleb, A.E. Elmasry, Y. Elshaier, An overview on pharmaceutical applications of phosphodiesterase enzyme 5 (PDE5) inhibitors, Mol Divers (2024) Online ahead of print.","DOI":"10.1007\/s11030-024-11016-2"},{"key":"10.1016\/j.bcp.2025.117363_b0170","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.biopha.2017.07.084","article-title":"A comprehensive review on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases","volume":"94","author":"Shafiee-Nick","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2025.117363_b0175","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-3-540-68964-5_13","article-title":"NO-independent, haem-dependent soluble guanylate cyclase stimulators","author":"Stasch","year":"2009","journal-title":"Handb Exp Pharmacol (191)"},{"key":"10.1016\/j.bcp.2025.117363_b0180","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/978-3-540-68964-5_14","article-title":"NO- and haem-independent soluble guanylate cyclase activators","author":"Schmidt","year":"2009","journal-title":"Handb Exp Pharmacol (191)"},{"issue":"21","key":"10.1016\/j.bcp.2025.117363_b0185","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1111\/bph.15698","article-title":"Soluble GC stimulators and activators: past, present and future","volume":"181","author":"Sandner","year":"2024","journal-title":"Br. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.bcp.2025.117363_b0190","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1111\/cts.13677","article-title":"Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science","volume":"16","author":"Trujillo","year":"2023","journal-title":"Clin. Transl. Sci."},{"issue":"6825","key":"10.1016\/j.bcp.2025.117363_b0195","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35065611","article-title":"NO-independent regulatory site on soluble guanylate cyclase","volume":"410","author":"Stasch","year":"2001","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.bcp.2025.117363_b0200","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1182\/blood.V84.12.4226.bloodjournal84124226","article-title":"YC-1, a novel activator of platelet guanylate cyclase","volume":"84","author":"Ko","year":"1994","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.bcp.2025.117363_b0205","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1021\/jm010001h","article-title":"Synthesis of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole analogues as novel antiplatelet agents","volume":"44","author":"Lee","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117363_b0210","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2210-1-13","article-title":"NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272","volume":"1","author":"Becker","year":"2001","journal-title":"BMC Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2025.117363_b0215","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrd2038","article-title":"NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential","volume":"5","author":"Evgenov","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.bcp.2025.117363_b0220","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/cmdc.200900014","article-title":"Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension","volume":"4","author":"Mittendorf","year":"2009","journal-title":"ChemMedChem"},{"issue":"4","key":"10.1016\/j.bcp.2025.117363_b0225","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"H.A. Ghofrani, N. Galie, F. Grimminger, E. Grunig, M. Humbert, Z.C. Jing, A.M. Keogh, D. Langleben, M.O. Kilama, A. Fritsch, D. Neuser, L.J. Rubin, P.-S. Group","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bcp.2025.117363_b0230","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1183\/09031936.00039808","article-title":"First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension","volume":"33","author":"Grimminger","year":"2009","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.bcp.2025.117363_b0235","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"H.A. Ghofrani, A.M. D'Armini, F. Grimminger, M.M. Hoeper, P. Jansa, N.H. Kim, E. Mayer, G. Simonneau, M.R. Wilkins, A. Fritsch, D. Neuser, G. Weimann, C. Wang, C.-S. Group","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.bcp.2025.117363_b0240","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with Heart failure and Reduced Ejection Fraction","volume":"382","author":"P.W. Armstrong, B. Pieske, K.J. Anstrom, J. Ezekowitz, A.F. Hernandez, J. Butler, C.S.P. Lam, P. Ponikowski, A.A. Voors, G. Jia, S.E. McNulty, M.J. Patel, L. Roessig, J. Koglin, C.M. O'Connor, V.S. Group","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.bcp.2025.117363_b0245","article-title":"Blood pressure and Safety events with Vericiguat in the VICTORIA Trial","volume":"10","author":"C.S.P. Lam, H. Mulder, Y. Lopatin, J.B. Vazquez-Tanus, D. Siu, J. Ezekowitz, B. Pieske, C.M. O'Connor, L. Roessig, M.J. Patel, K.J. Anstrom, A.F. Hernandez, P.W. Armstrong, V.S. Group","year":"2021","journal-title":"J. Am. Heart Assoc."},{"issue":"3","key":"10.1016\/j.bcp.2025.117363_b0250","doi-asserted-by":"crossref","first-page":"180","DOI":"10.36290\/vnl.2021.041","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"67","author":"Spinar","year":"2021","journal-title":"Vnitr. Lek."},{"issue":"18","key":"10.1016\/j.bcp.2025.117363_b0255","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1161\/CIRCULATIONAHA.121.056797","article-title":"Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in patients with Heart failure and Reduced Ejection Fraction (VICTORIA)","volume":"144","author":"Ezekowitz","year":"2021","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.bcp.2025.117363_b0260","first-page":"664","article-title":"Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue distribution","volume":"365","author":"Tobin","year":"2018","journal-title":"Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease, J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.bcp.2025.117363_b0265","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2215\/CJN.08410520","article-title":"Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: a Randomized Placebo-Controlled Clinical Trial","volume":"16","author":"Hanrahan","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"15","key":"10.1016\/j.bcp.2025.117363_b0270","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1001\/jama.2020.16641","article-title":"Effect of Praliciguat on Peak Rate of Oxygen Consumption in patients with Heart failure with Preserved Ejection Fraction: the CAPACITY HFpEF Randomized Clinical Trial","volume":"324","author":"Udelson","year":"2020","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.bcp.2025.117363_b0275","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1111\/bph.15492","article-title":"Olinciguat, a stimulator of soluble guanylyl cyclase, attenuates inflammation, vaso-occlusion and nephropathy in mouse models of sickle cell disease","volume":"178","author":"Tchernychev","year":"2021","journal-title":"Br. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.bcp.2025.117363_b0280","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1111\/bcp.15861","article-title":"Randomized placebo-controlled crossover study to assess tolerability and pharmacodynamics of zagociguat, a soluble guanylyl cyclase stimulator, in healthy elderly","volume":"89","author":"van Kraaij","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2025.117363_b0285","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/cts.13537","article-title":"First-in-human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS-penetrant soluble guanylyl cyclase stimulator","volume":"16","author":"van Kraaij","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.bcp.2025.117363_b0290","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.656561","article-title":"The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 reveals its Therapeutic potential in Neurodegenerative Diseases","volume":"12","author":"Correia","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"11","key":"10.1016\/j.bcp.2025.117363_b0295","doi-asserted-by":"crossref","first-page":"7280","DOI":"10.1021\/acs.jmedchem.2c02082","article-title":"New Generation of sGC Stimulators: Discovery of Imidazo[1,2-a]pyridine Carboxamide BAY 1165747 (BAY-747), a Long-Acting Soluble Guanylate Cyclase Stimulator for the Treatment of Resistant Hypertension","volume":"66","author":"Vakalopoulos","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117363_b0300","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1359939","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of a soluble guanylate cyclase stimulator, HEC95468, in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial","volume":"15","author":"Gui","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2025.117363_b0305","doi-asserted-by":"crossref","DOI":"10.3390\/ph17091140","article-title":"Inhibition of P-Glycoprotein Asymmetrically Alters the In Vivo Exposure Profile of SGC003F: a Novel Guanylate Cyclase Stimulator","volume":"17","author":"Lou","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bcp.2025.117363_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.107065","article-title":"Effects of an inhaled soluble guanylate cyclase (sGC) stimulator MK-5475 in pulmonary arterial hypertension (PAH)","volume":"206","author":"Bajwa","year":"2023","journal-title":"Respir. Med."},{"issue":"5","key":"10.1016\/j.bcp.2025.117363_b0315","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/sj.bjp.0704778","article-title":"NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle","volume":"136","author":"Stasch","year":"2002","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117363_b0320","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11897-010-0045-1","article-title":"Soluble guanylate cyclase modulators in heart failure","volume":"8","author":"Mitrovic","year":"2011","journal-title":"Curr. Heart Fail. Rep."},{"issue":"5","key":"10.1016\/j.bcp.2025.117363_b0325","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/HYPERTENSIONAHA.106.083832","article-title":"Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure","volume":"49","author":"Boerrigter","year":"2007","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.bcp.2025.117363_b0330","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s11886-023-01884-9","article-title":"Soluble Guanylate Cyclase Activators and Stimulators in patients with Heart failure","volume":"25","author":"Liang","year":"2023","journal-title":"Curr. Cardiol. Rep."},{"issue":"21","key":"10.1016\/j.bcp.2025.117363_b0335","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1161\/CIRCULATIONAHA.108.800292","article-title":"Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure","volume":"119","author":"Lapp","year":"2009","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.bcp.2025.117363_b0340","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/eurheartj\/ehs196","article-title":"Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure","volume":"34","author":"Erdmann","year":"2013","journal-title":"Eur. Heart J."},{"issue":"9","key":"10.1016\/j.bcp.2025.117363_b0345","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/eurjhf\/hfs093","article-title":"Coordinators, Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes","volume":"14","author":"Gheorghiade","year":"2012","journal-title":"Eur. J. Heart Fail."},{"issue":"6","key":"10.1016\/j.bcp.2025.117363_b0350","doi-asserted-by":"crossref","first-page":"H1347","DOI":"10.1152\/ajpheart.00544.2011","article-title":"Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia\/reperfusion injury: role of hydrogen sulfide","volume":"302","author":"Salloum","year":"2012","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117363_b0355","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1124\/mol.105.018747","article-title":"Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase","volume":"69","author":"Schindler","year":"2006","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117363_b0360","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000104091","article-title":"Blood pressure-independent effect of long-term treatment with the soluble heme-independent guanylyl cyclase activator HMR1766 on progression in a model of noninflammatory chronic renal damage","volume":"30","author":"Benz","year":"2007","journal-title":"Kidney Blood Press. Res."},{"issue":"12","key":"10.1016\/j.bcp.2025.117363_b0365","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1161\/01.ATV.0000249407.92147.12","article-title":"Soluble guanylyl cyclase activation with HMR1766 attenuates platelet activation in diabetic rats","volume":"26","author":"Schafer","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117363_b0370","doi-asserted-by":"crossref","first-page":"L658","DOI":"10.1152\/ajplung.00189.2009","article-title":"The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice","volume":"297","author":"Weissmann","year":"2009","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"issue":"5","key":"10.1016\/j.bcp.2025.117363_b0375","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.phrs.2010.06.008","article-title":"Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure","volume":"62","author":"Schafer","year":"2010","journal-title":"Pharmacol. Res."},{"issue":"9","key":"10.1016\/j.bcp.2025.117363_b0380","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1021\/acs.jmedchem.0c02154","article-title":"Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042)","volume":"64","author":"Hahn","year":"2021","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bcp.2025.117363_b0385","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1111\/dom.15099","article-title":"Safety, tolerability, pharmacodynamics and pharmacokinetics of the soluble guanylyl cyclase activator BI 685509 in patients with diabetic kidney disease: a randomized trial","volume":"25","author":"Cherney","year":"2023","journal-title":"Diabetes Obes. Metab."},{"issue":"3","key":"10.1016\/j.bcp.2025.117363_b0390","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1124\/jpet.122.001423","article-title":"The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease","volume":"384","author":"Reinhart","year":"2023","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2025.117363_b0395","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s40262-025-01503-6","article-title":"Pharmacokinetics and Lung Deposition after Administration of Inhaled Mosliciguat (BAY 1237592): results from Randomized phase I Studies in healthy men","volume":"64","author":"Saleh","year":"2025","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.bcp.2025.117363_b0400","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12931-022-02189-1","article-title":"Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC","volume":"23","author":"Becker-Pelster","year":"2022","journal-title":"Respir. Res."},{"issue":"13","key":"10.1016\/j.bcp.2025.117363_b0405","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1093\/cvr\/cvz161","article-title":"Small animal models of heart failure","volume":"115","author":"Riehle","year":"2019","journal-title":"Cardiovasc. Res."},{"issue":"3","key":"10.1016\/j.bcp.2025.117363_b0410","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/01.fjc.0000210071.54828.9b","article-title":"Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats","volume":"47","author":"Zanfolin","year":"2006","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2025.117363_b0415","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/01.HYP.0000241087.12492.47","article-title":"Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats","volume":"48","author":"Masuyama","year":"2006","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.bcp.2025.117363_b0420","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/hr.2009.64","article-title":"Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart","volume":"32","author":"Masuyama","year":"2009","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.bcp.2025.117363_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173978","article-title":"Soluble guanylate cyclase chronic stimulation effects on cardiovascular reactivity in cafeteria diet-induced rat model of metabolic syndrome","volume":"899","author":"Doghri","year":"2021","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117363_b0430","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/sj.bjp.0704483","article-title":"Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies","volume":"135","author":"Stasch","year":"2002","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117363_b0435","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96006","article-title":"Nitric oxide-sensitive guanylyl cyclase stimulation improves experimental heart failure with preserved ejection fraction","volume":"3","author":"Wilck","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.bcp.2025.117363_b0440","doi-asserted-by":"crossref","first-page":"A57","DOI":"10.1186\/2050-6511-16-S1-A57","article-title":"The sGC stimulator BAY 41-8543 in a rat model of hypertension-induced heart failure","author":"Haase","year":"2015","journal-title":"BMC Pharmacol. Toxicol."},{"issue":"6","key":"10.1016\/j.bcp.2025.117363_b0445","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1097\/HJH.0000000000004009","article-title":"The treatment with soluble guanylate cyclase stimulator BAY41-8543 prevents malignant hypertension and associated organ damage","volume":"43","author":"Huttl","year":"2025","journal-title":"J. Hypertens."},{"key":"10.1016\/j.bcp.2025.117363_b0450","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fphar.2012.00128","article-title":"Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress","volume":"3","author":"Costell","year":"2012","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2025.117363_b0455","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1097\/HJH.0b013e32833b558c","article-title":"Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models","volume":"28","author":"Sharkovska","year":"2010","journal-title":"J. Hypertens."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2025.117363_b0460","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.rmed.2016.08.022","article-title":"Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence","volume":"122","author":"Sandner","year":"2017","journal-title":"Respir. Med."},{"key":"10.1016\/j.bcp.2025.117363_b0465","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijcard.2016.04.098","article-title":"Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice","volume":"216","author":"Pradhan","year":"2016","journal-title":"Int. J. Cardiol."},{"issue":"11","key":"10.1016\/j.bcp.2025.117363_b0470","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1111\/bph.15333","article-title":"Stimulation of soluble guanylyl cyclase (sGC) by riociguat attenuates heart failure and pathological cardiac remodelling","volume":"179","author":"Rudebusch","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117363_b0475","doi-asserted-by":"crossref","first-page":"F148","DOI":"10.1152\/ajprenal.00247.2019","article-title":"Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure","volume":"318","author":"Shea","year":"2020","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"12","key":"10.1016\/j.bcp.2025.117363_b0480","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1021\/acs.jmedchem.7b00449","article-title":"Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart failure","volume":"60","author":"Follmann","year":"2017","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2025.117363_b0485","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.008735","article-title":"Vericiguat Improves Aortic Wave Reflection Parameters in a New Preclinical Model of Hypertension","volume":"15","author":"Boden","year":"2022","journal-title":"Circ. Heart Fail."},{"issue":"7","key":"10.1016\/j.bcp.2025.117363_b0490","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1253\/circj.CJ-24-0659","article-title":"Soluble Guanylate Cyclase Stimulator Vericiguat Attenuates Angiotensin II-Induced Oxidative stress and Cardiac Remodeling","volume":"89","author":"Harada","year":"2025","journal-title":"Circ J"},{"key":"10.1016\/j.bcp.2025.117363_b0495","first-page":"419","article-title":"Olinciguat, an Oral sGC Stimulator","volume":"11","author":"Zimmer","year":"2020","journal-title":"Exhibits Diverse Pharmacology across Preclinical Models of Cardiovascular, Metabolic, Renal, and Inflammatory Disease, Front Pharmacol"},{"key":"10.1016\/j.bcp.2025.117363_b0500","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3389\/fphys.2020.00345","article-title":"Enhanced Cardiomyocyte Function in Hypertensive Rats with Diastolic Dysfunction and Human Heart failure patients after Acute Treatment with Soluble Guanylyl Cyclase (sGC) Activator","volume":"11","author":"Kolijn","year":"2020","journal-title":"Front. Physiol."},{"issue":"10","key":"10.1016\/j.bcp.2025.117363_b0505","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/CIRCULATIONAHA.110.943431","article-title":"Differential cardiac remodeling in preload versus afterload","volume":"122","author":"Toischer","year":"2010","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.bcp.2025.117363_b0510","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1006\/phrs.1999.0652","article-title":"Animal models of chronic heart failure","volume":"41","author":"Muders","year":"2000","journal-title":"Pharmacol. Res."},{"issue":"5","key":"10.1016\/j.bcp.2025.117363_b0515","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1161\/01.CIR.0000055737.15443.F8","article-title":"Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure","volume":"107","author":"Boerrigter","year":"2003","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.bcp.2025.117363_b0520","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1007\/s00210-023-02561-y","article-title":"The treatment with sGC stimulator improves survival of hypertensive rats in response to volume-overload induced by aorto-caval fistula","volume":"396","author":"Gawrys","year":"2023","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117363_b0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121929","article-title":"Vericiguat preserved cardiac function and mitochondrial quality in a rat model of mitral regurgitation","volume":"328","author":"Jungtanasomboon","year":"2023","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.bcp.2025.117363_b0530","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.kint.2024.10.025","article-title":"Activating soluble guanylyl cyclase attenuates ischemic kidney damage","volume":"107","author":"Lichtenberger","year":"2025","journal-title":"Kidney Int."},{"issue":"17","key":"10.1016\/j.bcp.2025.117363_b0535","doi-asserted-by":"crossref","first-page":"13226","DOI":"10.3390\/ijms241713226","article-title":"The sGC Activator Runcaciguat has Kidney protective Effects and Prevents a Decline of Kidney Function in ZSF1 Rats","volume":"24","author":"Kraehling","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.bcp.2025.117363_b0540","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/ndt\/gfae261","article-title":"The soluble guanylate cyclase activator runcaciguat significantly improves albuminuria in patients with chronic kidney disease: a randomized placebo-controlled clinical trial","volume":"40","author":"Gansevoort","year":"2025","journal-title":"Nephrol. Dial. Transplant."},{"issue":"21","key":"10.1016\/j.bcp.2025.117363_b0545","doi-asserted-by":"crossref","first-page":"8118","DOI":"10.3390\/ijms21218118","article-title":"Ischemic Heart Disease Pathophysiology Paradigms Overview: from Plaque Activation to Microvascular Dysfunction","volume":"21","author":"Severino","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.bcp.2025.117363_b0550","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1161\/CIRCRESAHA.118.313568","article-title":"Medical Therapy for Heart failure Caused by Ischemic Heart Disease","volume":"124","author":"Elgendy","year":"2019","journal-title":"Circ. Res."},{"key":"10.1016\/j.bcp.2025.117363_b0555","doi-asserted-by":"crossref","unstructured":"E.H. Mace, M.J. Kimlinger, F.T.t. Billings, M.G. Lopez, Targeting Soluble Guanylyl Cyclase during Ischemia and Reperfusion, Cells 12(14) (2023) 1903.","DOI":"10.3390\/cells12141903"},{"issue":"5","key":"10.1016\/j.bcp.2025.117363_b0560","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1139\/Y07-033","article-title":"Investigation of the vasorelaxant effects of 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole (YC-1) and diethylamine\/nitric oxide (DEA\/NO) on the human radial artery used as coronary bypass graft","volume":"85","author":"Berkan","year":"2007","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117363_b0565","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.838","article-title":"Alteration of the soluble guanylate cyclase system in coronary arteries of high cholesterol diet-fed rabbits","volume":"9","author":"Tawa","year":"2021","journal-title":"Pharmacol. Res. Perspect."},{"issue":"3","key":"10.1016\/j.bcp.2025.117363_b0570","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00210-014-1083-0","article-title":"Vasorelaxing effects of the soluble guanylyl cyclase activator BAY 60-2770 in nitrate-tolerant monkey and canine coronary arteries","volume":"388","author":"Tawa","year":"2015","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117363_b0575","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1038\/s41598-025-88938-w","article-title":"Vericiguat prevents high glucose-mediated impaired vascular smooth muscle cGMP production and vasorelaxation","volume":"15","author":"Polhemus","year":"2025","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.bcp.2025.117363_b0580","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1073\/pnas.95.9.4888","article-title":"Mechanism of platelet inhibition by nitric oxide: in vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase","volume":"95","author":"Wang","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.bcp.2025.117363_b0585","doi-asserted-by":"crossref","first-page":"18B","DOI":"10.1016\/0002-9149(92)90590-U","article-title":"Antiplatelet and antithrombotic effects of organic nitrates","volume":"70","author":"Loscalzo","year":"1992","journal-title":"Am. J. Cardiol."},{"issue":"12","key":"10.1016\/j.bcp.2025.117363_b0590","doi-asserted-by":"crossref","first-page":"662","DOI":"10.21037\/atm-22-2583","article-title":"Soluble guanylate cyclase (sGC) stimulator vericiguat alleviates myocardial ischemia-reperfusion injury by improving microcirculation","volume":"10","author":"Cai","year":"2022","journal-title":"Ann Transl Med"},{"issue":"12","key":"10.1016\/j.bcp.2025.117363_b0595","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0295566","article-title":"Vericiguat protects against cardiac damage in a pig model of ischemia\/reperfusion","volume":"18","author":"Zhu","year":"2023","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.bcp.2025.117363_b0600","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083910","article-title":"Riociguat reduces infarct size and post-infarct heart failure in mouse hearts: insights from MRI\/PET imaging","volume":"8","author":"Methner","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bcp.2025.117363_b0605","doi-asserted-by":"crossref","first-page":"5358","DOI":"10.1038\/s41598-020-62156-y","article-title":"Stimulation of soluble guanylate cyclase improves donor organ function in rat heart transplantation","volume":"10","author":"Benke","year":"2020","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.bcp.2025.117363_b0610","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jacbts.2023.02.017","article-title":"Stimulation of Erythrocyte Soluble Guanylyl Cyclase Induces cGMP Export and Cardioprotection in Type 2 Diabetes","volume":"8","author":"Jiao","year":"2023","journal-title":"JACC Basic Transl Sci"},{"issue":"17","key":"10.1016\/j.bcp.2025.117363_b0615","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167693","article-title":"Hypoxic erythrocytes mediate cardioprotection through activation of soluble guanylate cyclase and release of cyclic GMP","volume":"133","author":"Yang","year":"2023","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.bcp.2025.117363_b0620","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00395-014-0421-1","article-title":"Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition","volume":"109","author":"Fraccarollo","year":"2014","journal-title":"Basic Res. Cardiol."},{"issue":"13","key":"10.1016\/j.bcp.2025.117363_b0625","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/eurheartj\/ehp143","article-title":"BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts","volume":"30","author":"Krieg","year":"2009","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.bcp.2025.117363_b0630","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1093\/cvr\/cvy039","article-title":"Cardioprotection by ischemic postconditioning and cyclic guanosine monophosphate-elevating agents involves cardiomyocyte nitric oxide-sensitive guanylyl cyclase","volume":"114","author":"Frankenreiter","year":"2018","journal-title":"Cardiovasc. Res."},{"issue":"24","key":"10.1016\/j.bcp.2025.117363_b0635","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1161\/CIRCULATIONAHA.117.028723","article-title":"cGMP-elevating Compounds and Ischemic Conditioning provide Cardioprotection against Ischemia and Reperfusion Injury via Cardiomyocyte-specific BK Channels","volume":"136","author":"Frankenreiter","year":"2017","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.bcp.2025.117363_b0640","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/CIRCULATIONAHA.109.870774","article-title":"Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury","volume":"120","author":"Korkmaz","year":"2009","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.bcp.2025.117363_b0645","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180207","article-title":"Cardioprotective effects of PKG activation by soluble GC activator, BAY 60-2770, in ischemia-reperfusion-injured rat hearts","volume":"12","author":"Lee","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bcp.2025.117363_b0650","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1124\/jpet.123.001918","article-title":"Efficacy of BAY 60-2770, a Soluble Guanylate Cyclase Activator, for Coronary Spasm in Animal Models","volume":"390","author":"Tawa","year":"2024","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2025.117363_b0655","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jaccao.2022.01.101","article-title":"The Role of Cardioprotection in Cancer Therapy Cardiotoxicity: JACC: CardioOncology State-of-the-Art Review","volume":"4","author":"Omland","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10.1016\/j.bcp.2025.117363_b0660","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1097\/MJT.0000000000000453","article-title":"Mechanisms and Genetic Susceptibility of Chemotherapy-Induced Cardiotoxicity in patients with Breast Cancer","volume":"24","author":"Mihalcea","year":"2017","journal-title":"Am. J .Ther."},{"issue":"3","key":"10.1016\/j.bcp.2025.117363_b0665","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jaccao.2020.06.010","article-title":"Doxorubicin-Induced Oxidative stress and Endothelial Dysfunction in Conduit arteries is prevented by Mitochondrial-specific Antioxidant Treatment","volume":"2","author":"Clayton","year":"2020","journal-title":"Jacc-Cardiooncol"},{"issue":"2","key":"10.1016\/j.bcp.2025.117363_b0670","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40256-021-00487-5","article-title":"The sGC-cGMP Signaling Pathway as a potential Therapeutic Target in Doxorubicin-Induced Heart failure: a Narrative Review","volume":"22","author":"Cho","year":"2022","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"3","key":"10.1016\/j.bcp.2025.117363_b0675","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3390\/biomedicines10030602","article-title":"Reactive Oxygen Species Induced Pathways in Heart failure Pathogenesis and potential Therapeutic strategies","volume":"10","author":"Mongirdiene","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.bcp.2025.117363_b0680","series-title":"The sGC stimulator (BAY41-8543) improves the survival of rats with DOXO-induced HFrEF with nephrotic syndrome, cGMP: Generators","author":"Gawrys","year":"2024"},{"key":"10.1016\/j.bcp.2025.117363_b0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2020.109190","article-title":"BAY60-2770 attenuates doxorubicin-induced cardiotoxicity by decreased oxidative stress and enhanced autophagy","volume":"328","author":"Zhao","year":"2020","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bcp.2025.117363_b0690","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.trsl.2024.07.005","article-title":"Vericiguat attenuates doxorubicin-induced cardiotoxicity through the PRKG1\/PINK1\/STING axis","volume":"273","author":"Zeng","year":"2024","journal-title":"Transl. Res."},{"key":"10.1016\/j.bcp.2025.117363_b0695","doi-asserted-by":"crossref","unstructured":"W. Chen, Y. Wu, W. Li, M. Song, K. Xu, M. Wu, L. Lin, Vericiguat improves cardiac remodelling and function in rats with doxorubicin-induced cardiomyopathy, ESC Heart Fail (2025).","DOI":"10.1002\/ehf2.15186"},{"issue":"7","key":"10.1016\/j.bcp.2025.117363_b0700","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1136\/annrheumdis-2013-204508","article-title":"Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFbeta signalling","volume":"74","author":"Beyer","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2025.117363_b0705","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejphar.2007.06.036","article-title":"Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase","volume":"572","author":"Dunkern","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117363_b0710","first-page":"3423","article-title":"Anti-remodeling potencies of the soluble guanylate cyclase activator BAY 41-2272 in human lung fibroblasts","volume":"44","author":"Lambers","year":"2014","journal-title":"Eur. Respir. J."},{"issue":"11","key":"10.1016\/j.bcp.2025.117363_b0715","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/01.RES.0000191538.76771.66","article-title":"Nitric oxide regulates transforming growth factor-beta signaling in endothelial cells","volume":"97","author":"Saura","year":"2005","journal-title":"Circ. Res."},{"issue":"7","key":"10.1016\/j.bcp.2025.117363_b0720","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021853","article-title":"Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats","volume":"6","author":"Geschka","year":"2011","journal-title":"PLoS One"},{"issue":"S1","key":"10.1016\/j.bcp.2025.117363_b0725","doi-asserted-by":"crossref","first-page":"O9","DOI":"10.1186\/1471-2210-11-S1-O9","article-title":"Nitric oxide-independent stimulation of soluble guanylate cyclase attenuates pulmonary fibrosis","volume":"11","author":"Evgenov","year":"2011","journal-title":"BMC Pharmacol."},{"issue":"11","key":"10.1016\/j.bcp.2025.117363_b0730","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1042\/CS20241204","article-title":"Angiotensin II-induced cardiac fibrosis and dysfunction are exacerbated by deletion of cGKI in periostin+ myofibroblasts","volume":"139","author":"Santos","year":"2025","journal-title":"Clin. Sci. (Lond.)"},{"issue":"13","key":"10.1016\/j.bcp.2025.117363_b0735","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1161\/CIRCULATIONAHA.123.066523","article-title":"Reactivation of Oxidized Soluble Guanylate Cyclase as a Novel Treatment Strategy to Slow Progression of Calcific Aortic Valve Stenosis: Preclinical and Randomized Clinical Trials to Assess Safety and Efficacy","volume":"151","author":"Zhang","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2025.117363_b0740","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1205475","article-title":"Hypertensive heart disease: risk factors, complications and mechanisms","volume":"10","author":"Masenga","year":"2023","journal-title":"Front. Cardiovasc. Med."},{"issue":"8","key":"10.1016\/j.bcp.2025.117363_b0745","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/ejhf.1835","article-title":"Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients","volume":"22","author":"Cautela","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"1","key":"10.1016\/j.bcp.2025.117363_b0750","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/jvd3010009","article-title":"Guanylyl Cyclase Activator Improves Endothelial Function by Decreasing Superoxide Anion Concentration","volume":"3","author":"Martinelli","year":"2024","journal-title":"Journal of Vascular Diseases"},{"issue":"1","key":"10.1016\/j.bcp.2025.117363_b0755","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/1074248412455696","article-title":"Nitric oxide- and heme-independent activation of soluble guanylate cyclase attenuates peroxynitrite-induced endothelial dysfunction in rat aorta","volume":"18","author":"Korkmaz","year":"2013","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2025.117363_b0760","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300335","article-title":"Vasodilators for Acute Heart failure - a Systematic Review with Meta-Analysis","volume":"3","author":"Lukoschewitz","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.bcp.2025.117363_b0765","doi-asserted-by":"crossref","unstructured":"D. Bonderman, S. Ghio, S.B. Felix, H.A. Ghofrani, E. Michelakis, V. Mitrovic, R.J. Oudiz, F. Boateng, A.V. Scalise, L. Roessig, M.J. Semigran, G. Left Ventricular Systolic Dysfunction Associated With Pulmonary Hypertension Riociguat Trial Study, Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study, Circulation 128(5) (2013) 502-11.","DOI":"10.1161\/CIRCULATIONAHA.113.001458"},{"issue":"10","key":"10.1016\/j.bcp.2025.117363_b0770","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.healun.2021.06.020","article-title":"Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","volume":"40","author":"Benza","year":"2021","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"10.1016\/j.bcp.2025.117363_b0775","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/annrheumdis-2015-209087","article-title":"Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2","volume":"76","author":"Humbert","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2025.117363_b0780","first-page":"S86","article-title":"Population pharmacokinetics and the pharmacokinetic\/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension","volume":"6","author":"Saleh","year":"2016","journal-title":"Pulm Circ"},{"issue":"5","key":"10.1016\/j.bcp.2025.117363_b0785","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1183\/09031936.00090614","article-title":"Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)","volume":"45","author":"Rubin","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.bcp.2025.117363_b0790","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-2600(16)30019-4","article-title":"Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial","volume":"4","author":"Ghofrani","year":"2016","journal-title":"Lancet Respir. Med."},{"issue":"8","key":"10.1016\/j.bcp.2025.117363_b0795","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1136\/heartjnl-2016-309621","article-title":"Haemodynamic effects of riociguat in inoperable\/recurrent chronic thromboembolic pulmonary hypertension","volume":"103","author":"Kim","year":"2017","journal-title":"Heart"},{"issue":"7","key":"10.1016\/j.bcp.2025.117363_b0800","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1111\/bcp.14676","article-title":"Riociguat: Clinical research and evolving role in therapy","volume":"87","author":"Klinger","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2025.117363_b0805","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/ejhf.135","article-title":"Coordinators, Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES)","volume":"16","author":"Pieske","year":"2014","journal-title":"Eur. J. Heart Fail."},{"issue":"22","key":"10.1016\/j.bcp.2025.117363_b0810","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1136\/heartjnl-2015-307832","article-title":"Riociguat for pulmonary arterial hypertension associated with congenital heart disease","volume":"101","author":"Rosenkranz","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.bcp.2025.117363_b0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112894","article-title":"Development of vericiguat: the first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF)","volume":"149","author":"Xia","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"21","key":"10.1016\/j.bcp.2025.117363_b0820","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.2015.15734","article-title":"Coordinators, effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in patients with Worsening Chronic Heart failure and Reduced Ejection Fraction: the SOCRATES-REDUCED Randomized Trial","volume":"314","author":"Gheorghiade","year":"2015","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.bcp.2025.117363_b0825","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/eurheartj\/ehw561","article-title":"What can we learn from SOCRATES: more questions than answers?","volume":"38","author":"Cleland","year":"2017","journal-title":"Eur. Heart J."},{"issue":"8","key":"10.1016\/j.bcp.2025.117363_b0830","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/CIRCULATIONAHA.120.047086","article-title":"Comparing the Benefit of Novel Therapies across Clinical Trials: Insights from the VICTORIA Trial","volume":"142","author":"Butler","year":"2020","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.bcp.2025.117363_b0835","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jchf.2020.08.008","article-title":"N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart failure with Reduced Ejection Fraction Study","volume":"8","author":"Ezekowitz","year":"2020","journal-title":"JACC Heart Fail"},{"issue":"11","key":"10.1016\/j.bcp.2025.117363_b0840","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/ejhf.2720","article-title":"Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum","volume":"24","author":"Butler","year":"2022","journal-title":"Eur. J. Heart Fail."},{"issue":"6","key":"10.1016\/j.bcp.2025.117363_b0845","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1002\/ehf2.14050","article-title":"Vericiguat and NT-proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial","volume":"9","author":"Senni","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"2","key":"10.1016\/j.bcp.2025.117363_b0850","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ejhf.3501","article-title":"Vericiguat Global Study in Participants with Chronic Heart failure: Design of the VICTOR trial","volume":"27","author":"Reddy","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.bcp.2025.117363_b0855","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.3598","article-title":"Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: the VICTOR trial","author":"Saldarriaga","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.bcp.2025.117363_b0860","article-title":"Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial","author":"J. Butler, C.J. McMullan, K.J. Anstrom, I. Barash, M.P. Bonaca, M. Borentain, S. Corda, J.A. Ezekowitz, G.M. Felker, D. Gates, C.S.P. Lam, E.F. Lewis, J. Lindenfeld, R.J. Mentz, C.M. O'Connor, P. Ponikowski, Y.N.V. Reddy, G.M.C. Rosano, C. Saldarriaga, M. Senni, L. She, P.P. Teixeira, J. Udelson, A. Urbinati, V. Vlajnic, A.A. Voors, A. Xing, M.J. Patel, F. Zannad, V.S. Group","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2025.117363_b0865","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2025.08.054","article-title":"Pharmacological Treatment of Heart failure with Reduced Ejection Fraction: an Updated Systematic Review and Network Meta-Analysis","author":"van Essen","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bcp.2025.117363_b0870","article-title":"Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials","author":"F. Zannad, C.M. O'Connor, J. Butler, C.J. McMullan, K.J. Anstrom, I. Barash, M.P. Bonaca, M. Borentain, S. Corda, D. Gates, J.A. Ezekowitz, A.F. Hernandez, C.S.P. Lam, E.F. Lewis, J. Lindenfeld, R.J. Mentz, P. Ponikowski, Y.N.V. Reddy, G.M.C. Rosano, C. Saldarriaga, M. Senni, P.P. Teixeira, J. Udelson, A. Urbinati, V. Vlajnic, A.A. Voors, A. Xing, M.J. Patel, P.W. Armstrong, Victoria, V.S. Groups","year":"2025","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.bcp.2025.117363_b0875","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2021.100924","article-title":"Outcomes with sGC Therapy in patients with HFpEF: a Meta-Analysis of prior Trials","volume":"47","author":"Thakker","year":"2022","journal-title":"Curr. Probl. Cardiol."},{"issue":"15","key":"10.1016\/j.bcp.2025.117363_b0880","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","article-title":"Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study","volume":"38","author":"Pieske","year":"2017","journal-title":"Eur. Heart J."},{"issue":"15","key":"10.1016\/j.bcp.2025.117363_b0885","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of Vericiguat vs Placebo on Quality of Life in patients with Heart failure and Preserved Ejection Fraction: the VITALITY-HFpEF Randomized Clinical Trial","volume":"324","author":"P.W. Armstrong, C.S.P. Lam, K.J. Anstrom, J. Ezekowitz, A.F. Hernandez, C.M. O'Connor, B. Pieske, P. Ponikowski, S.J. Shah, S.D. Solomon, A.A. Voors, L. She, V. Vlajnic, F. Carvalho, L. Bamber, R.O. Blaustein, L. Roessig, J. Butler, V.I.-H.S. Group","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.bcp.2025.117363_b0890","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1378\/chest.14-0106","article-title":"Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study","volume":"146","author":"Bonderman","year":"2014","journal-title":"Chest"},{"issue":"36","key":"10.1016\/j.bcp.2025.117363_b0895","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1093\/eurheartj\/ehac389","article-title":"Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial","volume":"43","author":"Dachs","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bcp.2025.117363_b0900","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ahj.2021.07.003","article-title":"Impact of oral soluble guanylate cyclase stimulators in heart failure: a systematic review and Meta-analysis of randomized controlled trials","volume":"241","author":"Moghaddam","year":"2021","journal-title":"Am. Heart J."},{"issue":"3","key":"10.1016\/j.bcp.2025.117363_b0905","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/SHK.0000000000002277","article-title":"Soluble Guanylate Cyclase Stimulators in Heart failure with Preserved Ejection Fraction: a Systematic Review and Meta-Analysis","volume":"61","author":"Zhao","year":"2024","journal-title":"Shock"},{"issue":"24","key":"10.1016\/j.bcp.2025.117363_b0910","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1056\/NEJMoa1510774","article-title":"Isosorbide Mononitrate in Heart failure with Preserved Ejection Fraction","volume":"373","author":"Redfield","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.bcp.2025.117363_b0915","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.bcp.2025.117363_b0920","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrcardio.2014.83","article-title":"The pathophysiology of heart failure with preserved ejection fraction","volume":"11","author":"Borlaug","year":"2014","journal-title":"Nat. Rev. Cardiol."},{"issue":"3","key":"10.1016\/j.bcp.2025.117363_b0925","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.037567","article-title":"Phenotypic Trajectories from Acute to Stable phase in Heart failure with Preserved Ejection Fraction: Insights from the PURSUIT-HFpEF Study","volume":"14","author":"Matsuoka","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.bcp.2025.117363_b0930","doi-asserted-by":"crossref","unstructured":"A. Friebe, J.R. Kraehling, M. Russwurm, P. Sandner, A. Schmidtko, The 10th International Conference on cGMP 2022: recent trends in cGMP research and development-meeting report, Naunyn Schmiedebergs Arch Pharmacol 396(8) (2023) 1669-1686.","DOI":"10.1007\/s00210-023-02484-8"},{"issue":"11","key":"10.1016\/j.bcp.2025.117363_b0935","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119273","article-title":"Effects of Soluble Guanylate Cyclase Stimulators and Activators on Anti-Aggregatory Signalling in patients with Coronary Artery Spasm","volume":"24","author":"Muminovic","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2025.117363_b0940","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jaccas.2020.11.043","article-title":"Repurposing Riociguat for Treatment of Refractory Angina Resulting from Coronary Spasm","volume":"3","author":"Martinez Pereyra","year":"2021","journal-title":"JACC Case Rep"},{"issue":"1","key":"10.1016\/j.bcp.2025.117363_b0945","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s43044-024-00437-x","article-title":"Soluble guanylate cyclase stimulators for heart failure: a network meta-analysis and subgroup analyses of reduced and preserved ejection fraction","volume":"76","author":"Abuelazm","year":"2024","journal-title":"Egypt Heart J"},{"issue":"13","key":"10.1016\/j.bcp.2025.117363_b0950","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jacc.2021.07.050","article-title":"Low Blood pressure and Managing drugs in HF: where do SGLT2 Inhibitors stand?","volume":"78","author":"Girerd","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.bcp.2025.117363_b0955","doi-asserted-by":"crossref","first-page":"432","DOI":"10.7861\/clinmed.2023-2023-23.5.Cardio1","article-title":"Updates in heart failure","volume":"23","author":"Rees","year":"2023","journal-title":"Clin. Med. (Lond.)"},{"key":"10.1016\/j.bcp.2025.117363_b0960","doi-asserted-by":"crossref","first-page":"e03","DOI":"10.15420\/cfr.2023.20","article-title":"Initiation and Up-titration of Guideline-directed Medical Therapy for patients with Heart failure: Better, Faster, stronger!","volume":"10","author":"Carrizales-Sepulveda","year":"2024","journal-title":"Card. Fail. Rev."},{"issue":"1","key":"10.1016\/j.bcp.2025.117363_b0965","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1038\/s41598-024-57695-7","article-title":"The efficacy and safety of soluble guanylate cyclase modulation in patients with heart failure: a comprehensive meta-analysis of randomized controlled trials","volume":"14","author":"Arayici","year":"2024","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.bcp.2025.117363_b0970","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11886-020-01277-2","article-title":"Sepsis-Induced Cardiomyopathy: a Comprehensive Review","volume":"22","author":"L'Heureux","year":"2020","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.bcp.2025.117363_b0975","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40560-016-0148-1","article-title":"Sepsis-induced myocardial dysfunction: pathophysiology and management","volume":"4","author":"Kakihana","year":"2016","journal-title":"J. Intensive Care"},{"issue":"2","key":"10.1016\/j.bcp.2025.117363_b0980","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1161\/01.CIR.0000052622.51963.FC","article-title":"Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure","volume":"107","author":"Ezekowitz","year":"2003","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.bcp.2025.117363_b0985","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.030099","article-title":"Anemia and Iron Deficiency in Heart failure: Current Concepts and Emerging Therapies","volume":"138","author":"Anand","year":"2018","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.bcp.2025.117363_b0990","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40256-022-00557-2","article-title":"Vericiguat: a Randomized, phase Ib, Placebo-Controlled, Double-blind, QTc Interval Study in patients with Chronic Coronary Syndromes","volume":"23","author":"Bottcher","year":"2023","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"6","key":"10.1016\/j.bcp.2025.117363_b0995","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/cpt.2574","article-title":"Vericiguat in Combination with Short-Acting Nitroglycerin in patients with Chronic Coronary Syndromes: the Randomized","volume":"111","author":"Boettcher","year":"2022","journal-title":"Phase Ib, VENICE Study, Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.bcp.2025.117363_b1000","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/cts.13238","article-title":"Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: the randomized, phase Ib","volume":"15","author":"Boettcher","year":"2022","journal-title":"VISOR Study, Clin Transl Sci"},{"issue":"5","key":"10.1016\/j.bcp.2025.117363_b1005","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ejhf.2468","article-title":"Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction","volume":"24","author":"C. Saldarriaga, D. Atar, A. Stebbins, B.S. Lewis, I.Z. Abidin, R.O. Blaustein, J. Butler, J.A. Ezekowitz, A.F. Hernandez, C.S.P. Lam, C.M. O'Connor, B. Pieske, P. Ponikowski, L. Roessig, A.A. Voors, K.J. Anstrom, P.W. Armstrong, V.S. Group","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.bcp.2025.117363_b1010","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.15420\/cfr.2023.05","article-title":"Global Public Health Burden of Heart failure: an Updated Review","volume":"9","author":"Shahim","year":"2023","journal-title":"Card. Fail. Rev."},{"issue":"9","key":"10.1016\/j.bcp.2025.117363_b1015","first-page":"388","article-title":"Vericiguat: the Fifth Harmony of Heart failure with Reduced Ejection Fraction","volume":"10","author":"Falco","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"issue":"11","key":"10.1016\/j.bcp.2025.117363_b1020","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Committees, Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.bcp.2025.117363_b1025","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bcp.2025.117363_b1030","article-title":"Soluble Guanylate Cyclase Stimulators in Heart failure","volume":"13","author":"Kansakar","year":"2021","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.bcp.2025.117363_b1035","doi-asserted-by":"crossref","DOI":"10.3390\/cells9010242","article-title":"Cellular and Molecular differences between HFpEF and HFrEF: a step Ahead in an improved Pathological Understanding","volume":"9","author":"Simmonds","year":"2020","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.bcp.2025.117363_b1040","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000536","article-title":"The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction","volume":"2","author":"Greene","year":"2013","journal-title":"J. Am. Heart Assoc."},{"issue":"9","key":"10.1016\/j.bcp.2025.117363_b1045","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/cvr\/cvab240","article-title":"Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology","volume":"118","author":"Petraina","year":"2022","journal-title":"Cardiovasc. Res."},{"issue":"7","key":"10.1016\/j.bcp.2025.117363_b1050","article-title":"Cardiorenal Syndrome: a Literature Review","volume":"15","author":"Ajibowo","year":"2023","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.bcp.2025.117363_b1055","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11897-016-0290-z","article-title":"Soluble Guanylate Cyclase Stimulators: a Novel Treatment Option for Heart failure Associated with Cardiorenal Syndromes?","volume":"13","author":"Dubin","year":"2016","journal-title":"Curr. Heart Fail. Rep."},{"issue":"2","key":"10.1016\/j.bcp.2025.117363_b1060","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/cvr\/cvt257","article-title":"NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size","volume":"101","author":"Bice","year":"2014","journal-title":"Cardiovasc. Res."},{"issue":"2","key":"10.1016\/j.bcp.2025.117363_b1065","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/sj.bjp.0704484","article-title":"Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies","volume":"135","author":"Stasch","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117363_b1070","series-title":"Cardiovascular effects of the soluble guanylyl cyclase activator BAY 58\u20132667 in anesthetized dogs, 3rd International Conference on cGMP Generators","first-page":"P28","author":"Hoffmann","year":"2007"},{"issue":"2","key":"10.1016\/j.bcp.2025.117363_b1075","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ejcts.2010.05.025","article-title":"Pre-conditioning with the soluble guanylate cyclase activator Cinaciguat reduces ischaemia-reperfusion injury after cardiopulmonary bypass","volume":"39","author":"Radovits","year":"2011","journal-title":"Eur. J. Cardiothorac. Surg."},{"issue":"11","key":"10.1016\/j.bcp.2025.117363_b1080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044481","article-title":"The soluble guanylyl cyclase activator bay 58-2667 selectively limits cardiomyocyte hypertrophy","volume":"7","author":"Irvine","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2025.117363_b1085","first-page":"P30","article-title":"Chronic activation of heme free soluble guanylate cyclase leads to cardio-renal protection in experimental hypertension, BMC","author":"Hoffmann","year":"2013","journal-title":"Pharmacol. Toxicol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117363_b1090","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cvr\/cvp065","article-title":"Stimulation of cGMP signalling protects coronary endothelium against reperfusion-induced intercellular gap formation","volume":"83","author":"Kasseckert","year":"2009","journal-title":"Cardiovasc. Res."},{"issue":"12","key":"10.1016\/j.bcp.2025.117363_b1095","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1007\/s00210-021-02149-4","article-title":"Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease","volume":"394","author":"B\u00e9nardeau","year":"2021","journal-title":"N-S Arch Pharmacol"},{"issue":"8","key":"10.1016\/j.bcp.2025.117363_b1100","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/eurjhf\/hfs071","article-title":"Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design","volume":"14","author":"Ghio","year":"2012","journal-title":"Eur. J. Heart Fail."},{"issue":"23\u201324","key":"10.1016\/j.bcp.2025.117363_b1105","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s00508-016-1068-8","article-title":"Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction : Study protocol for a randomized controlled trial","volume":"128","author":"Mascherbauer","year":"2016","journal-title":"Wien. Klin. Wochenschr."},{"issue":"11","key":"10.1016\/j.bcp.2025.117363_b1110","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s40262-021-01024-y","article-title":"Population Pharmacokinetics and Pharmacodynamics of Vericiguat in patients with Heart failure and Reduced Ejection Fraction","volume":"60","author":"Ruehs","year":"2021","journal-title":"Clin. Pharmacokinet."},{"issue":"9","key":"10.1016\/j.bcp.2025.117363_b1115","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/ejhf.1787","article-title":"Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction","volume":"22","author":"Kramer","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"6","key":"10.1016\/j.bcp.2025.117363_b1120","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1001\/jamacardio.2020.6455","article-title":"Clinical Outcomes and Response to Vericiguat according to Index Heart failure event: Insights from the VICTORIA Trial","volume":"6","author":"C.S.P. Lam, A. Giczewska, K. Sliwa, F. Edelmann, J. Refsgaard, E. Bocchi, J.A. Ezekowitz, A.F. Hernandez, C.M. O'Connor, L. Roessig, M.J. Patel, B. Pieske, K.J. Anstrom, P.W. Armstrong, V.S. Group","year":"2021","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.bcp.2025.117363_b1125","article-title":"Clinical Outcome predictions for the VerICiguaT Global Study in Subjects with Heart failure with Reduced Ejection Fraction (VICTORIA) trial: VICTORIA Outcomes Model","author":"R.J. Mentz, H. Mulder, A. Mosterd, N.K. Sweitzer, M. Senni, J. Butler, J.A. Ezekowitz, C.S.P. Lam, B. Pieske, P. Ponikowski, A.A. Voors, K.J. Anstrom, P.W. Armstrong, C.M. O'Connor, V.S. Group","year":"2021","journal-title":"J. Card. Fail."},{"issue":"2","key":"10.1016\/j.bcp.2025.117363_b1130","first-page":"96","article-title":"Randomized, Double-blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: the VICTORIA Trial, JACC","volume":"6","author":"Armstrong","year":"2018","journal-title":"Heart Fail"},{"issue":"6","key":"10.1016\/j.bcp.2025.117363_b1135","article-title":"Vericiguat and Health-Related Quality of Life in patients with Heart failure with Reduced Ejection Fraction: Insights from the VICTORIA Trial","volume":"15","author":"J. Butler, A. Stebbins, V. Melenovsky, N.K. Sweitzer, M.R. Cowie, J. Stehlik, M.S. Khan, R.O. Blaustein, J.A. Ezekowitz, A.F. Hernandez, C.S.P. Lam, R. Nkulikiyinka, C.M. O'Connor, B.M. Pieske, P. Ponikowski, J.A. Spertus, A.A. Voors, K.J. Anstrom, P.W. Armstrong, V.S. Group","year":"2022","journal-title":"Circ. Heart Fail."},{"issue":"9","key":"10.1016\/j.bcp.2025.117363_b1140","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/ejhf.2608","article-title":"Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril\/valsartan: insights from the VICTORIA trial","volume":"24","author":"M. Senni, W.G. Alemayehu, D. Sim, F. Edelmann, J. Butler, J. Ezekowitz, A.F. Hernandez, C.S.P. Lam, C.M. O'Connor, B. Pieske, P. Ponikowski, L. Roessig, A.A. Voors, C.M. Westerhout, C. McMullan, P.W. Armstrong, V.S. Group","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.bcp.2025.117363_b1145","article-title":"Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial","author":"Butler","year":"2025","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bcp.2025.117363_b1150","article-title":"Effect of Vericiguat on Worsening Heart failure in Compensated Outpatients with HFrEF: Insights from VICTOR","author":"F. Zannad, Y.N.V. Reddy, I. Barash, K.J. Anstrom, M.P. Bonaca, M. Borentain, S. Corda, P.P. Teixeira, J.A. Ezekowitz, D. Gates, C.S.P. Lam, E.F. Lewis, J. Lindenfeld, C.J. McMullan, R.J. Mentz, C.M. O'Connor, P. Ponikowski, G.M.C. Rosano, C. Saldarriaga, M. Senni, J. Udelson, A. Urbinati, V. Vlajnic, A.A. Voors, A. Xing, M.J. Patel, J. Butler, V.S. Group","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.bcp.2025.117363_b1155","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ejhf.800","article-title":"Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study","volume":"19","author":"Filippatos","year":"2017","journal-title":"Eur. J. Heart Fail."},{"issue":"5","key":"10.1016\/j.bcp.2025.117363_b1160","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.005998","article-title":"Rationale and Design of the VITALITY-HFpEF Trial","volume":"12","author":"Butler","year":"2019","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.bcp.2025.117363_b1165","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ahj.2020.01.009","volume":"222","author":"Udelson","year":"2020","journal-title":"Am. Heart J."},{"issue":"S1","key":"10.1016\/j.bcp.2025.117363_b1170","doi-asserted-by":"crossref","first-page":"P51","DOI":"10.1186\/1471-2210-9-S1-P51","article-title":"Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure","volume":"9","author":"Mitrovic","year":"2009","journal-title":"BMC Pharmacol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225006288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225006288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:40:27Z","timestamp":1773294027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225006288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":234,"alternative-id":["S0006295225006288"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117363","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the potential of soluble guanylyl cyclase stimulators and activators in heart failure","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117363","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117363"}}